pain
Pain · 2015–2015
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| buprenorphine; oxycodone + naloxone Additional strengths of buprenorphine patches and oxycodone + naloxone tablets for pain management (non-cancer and cancer pain). | Jul 2015 | Deferred | no section in document |
| oxycodone hydrochloride Modified release tablet for pain management. The 5 mg strength was requested to provide prescribers with more flexibility when prescribing pain medications. | Mar 2015 | Not recommended | none received |
What the PBS pays
$419M in government benefit over 2024–25, across 9,520,929 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| buprenorphine; oxycodone + naloxone | $301M |
| oxycodone hydrochloride | $117.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.